Dergiler / Turkish Journal of Internal Medicine / 2022 / Supplement 1
Pembrolizumab Induced Hypothyroidism: A Case Report
- Sayfa
- 149–151
- DOI
- —
Abstract
Immune checkpoint inhibitors inhibit the inhibitory mechanism on the immune system, their side effects may be autoimmune diseases that occur due to excessive immune response. Pembrolizumab is an immune checkpoint inhibitor targeting PD-1. The most common clinical presentations of thyroid injury induced by pembrolizumab are destructive thyroiditis and overt hypothyroidism. Herein, we presented a case of pembrolizumab induced hypothyroidism.